Skip to main content
Salarius Pharmaceuticals, Inc. logo

Salarius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SLRX ISIN · US79400X4043 LEI · 549300CLUMLZXIHU7X22 US Professional, scientific and technical activities
Open in API
Filings indexed 700 across all filing types
Latest filing 2020-02-12 Capital/Financing Update
Country US United States of America
Listing US SLRX

About Salarius Pharmaceuticals, Inc.

https://salariuspharma.com/

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for cancer patients with high unmet medical needs. The company's core technology focuses on correcting the dysregulated gene expression of cancer cells, a key driver of disease development. Its pipeline includes two classes of drugs: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials, while the lead TPD candidate, SP-3164, is in IND-enabling studies. These therapeutic candidates are being developed to treat solid and hematologic cancers, including leukemias and lymphomas.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes details about a public offering of securities, issuance of Series A Convertible Preferred Stock, an underwriting agreement, and related press releases. It does not contain financial statements or detailed financial analysis but rather announces financing activities and related corporate actions. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is over 11,000 characters, indicating it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2020-02-12 English
424B4
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(4) related to a public offering of securities, including Class A Units and Class B Units consisting of common stock, preferred stock, and warrants. It includes detailed offering terms, underwriting discounts, risk factors, use of proceeds, and other information typical of a securities offering prospectus. The document is not an annual report, earnings release, or management discussion, but rather a capital raising document. It is not a brief announcement or a regulatory filing of a different nature. Therefore, the document fits the category of a Capital/Financing Update, which covers updates on company fundraising and financing activities.
2020-02-10 English
S-1MEF
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes details about the securities being registered, the offering price, and legal consents. This type of filing is related to capital raising activities and financing. It is not an annual report, earnings release, or any other financial report but a registration statement for securities offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed registration information, not just an announcement or notice, so it is not RPA or RNS.
2020-02-07 English
Regulatory Filings 2020
Regulatory Filings
2020-02-07 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A Registration Statement Amendment No. 2 filed with the SEC, dated February 6, 2020, for Salarius Pharmaceuticals, Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for public offering. The text includes detailed information about the securities being offered, underwriting, risk factors, and other disclosures typical of a registration statement prospectus. This is not an annual report, earnings release, or any other financial report but a capital raising filing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual filing, not just an announcement or certification.
2020-02-06 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 95% confidence The document is a letter from Ladenburg Thalmann & Co. Inc., the underwriters' representative, addressed to the SEC regarding a Registration Statement on Form S-1 for Salarius Pharmaceuticals, Inc. It specifically concurs with the acceleration request for the effective date of the registration statement. The content is related to a capital raising process and the registration of securities, which fits the category of Capital/Financing Update filings. The document is short (1125 characters) and is not a full report but an official communication about the offering process. Therefore, it should be classified as a Capital/Financing Update (CAP).
2020-02-05 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.